Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 790568, 7 pages
http://dx.doi.org/10.1155/2008/790568
Review Article

The Role of PPAR 𝜸 in the Cyclooxygenase Pathway in Lung Cancer

UCLA Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

Received 16 April 2008; Revised 18 June 2008; Accepted 8 July 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Saswati Hazra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Google Scholar
  2. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at PubMed
  3. H. Sasaki, M. Tanahashi, H. Yukiue et al., “Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer,” Lung Cancer, vol. 36, no. 1, pp. 71–76, 2002. View at Publisher · View at Google Scholar
  4. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. Y. Bren-Mattison, V. Van Putten, D. Chan, R. Winn, M. W. Geraci, and R. A. Nemenoff, “Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC),” Oncogene, vol. 24, no. 8, pp. 1412–1422, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. C. G. Su, X. Wen, S. T. Bailey et al., “A novel therapy for colitis utilizing PPAR-? ligands to inhibit the epithelial inflammatory response,” The Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999. View at Publisher · View at Google Scholar · View at PubMed
  7. T.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer,” Cancer Research, vol. 60, no. 4, pp. 1129–1138, 2000. View at Google Scholar
  8. S. Han and J. Roman, “Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?,” Anti-Cancer Drugs, vol. 18, no. 3, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. A. T. Coyle and B. T. Kinsella, “Synthetic peroxisome proliferator-activated receptor γ agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells,” Biochemical Pharmacology, vol. 71, no. 9, pp. 1308–1323, 2006. View at Publisher · View at Google Scholar · View at PubMed
  10. M. J. Betz, I. Shapiro, M. Fassnacht, S. Hahner, M. Reincke, and F. Beuschlein, “Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 7, pp. 3886–3896, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. T. Satoh, M. Toyoda, H. Hoshino et al., “Activation of peroxisome proliferator-activated receptor-? stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells,” Oncogene, vol. 21, no. 14, pp. 2171–2180, 2002. View at Publisher · View at Google Scholar · View at PubMed
  12. S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling, “Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity,” The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5845–5853, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. S. Hazra and S. M. Dubinett, “Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 77, no. 1, pp. 51–58, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. S. Hazra, R. K. Batra, H. H. Tai, S. Sharma, X. Cui, and S. M. Dubinett, “Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase,” Molecular Pharmacology, vol. 71, no. 6, pp. 1715–1720, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. M. Huang, M. Stolina, S. Sharma et al., “Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production,” Cancer Research, vol. 58, no. 6, pp. 1208–1216, 1998. View at Google Scholar
  16. T. Hida, Y. Yatabe, H. Achiwa et al., “Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas,” Cancer Research, vol. 58, no. 17, pp. 3761–3764, 1998. View at Google Scholar
  17. J. Brabender, J. Park, R. Metzger et al., “Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer,” Annals of Surgery, vol. 235, no. 3, pp. 440–443, 2002. View at Publisher · View at Google Scholar
  18. H. Achiwa, Y. Yatabe, T. Hida et al., “Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas,” Clinical Cancer Research, vol. 5, no. 5, pp. 1001–1005, 1999. View at Google Scholar
  19. Y. Hosomi, T. Yokose, Y. Hirose et al., “Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung,” Lung Cancer, vol. 30, no. 2, pp. 73–81, 2000. View at Publisher · View at Google Scholar
  20. M. Tsujii and R. N. DuBois, “Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2,” Cell, vol. 83, no. 3, pp. 493–501, 1995. View at Publisher · View at Google Scholar
  21. K. Krysan, F. H. Merchant, L. Zhu et al., “COX-2-dependent stabilization of survivin in non-small cell lung cancer,” The FASEB Journal, vol. 18, no. 1, pp. 206–208, 2004. View at Google Scholar
  22. K. Krysan, H. Dalwadi, S. Sharma, M. Põld, and S. Dubinett, “Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer,” Cancer Research, vol. 64, no. 18, pp. 6359–6362, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. K. M. Leahy, A. T. Koki, and J. L. Masferrer, “Role of cyclooxygenases in angiogenesis,” Current Medicinal Chemistry, vol. 7, no. 11, pp. 1163–1170, 2000. View at Google Scholar
  24. S. Gately and W. W. Li, “Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy,” Seminars in Oncology, vol. 31, no. 2, supplement 7, pp. 2–11, 2004. View at Google Scholar
  25. V. C. Liu, L. Y. Wong, T. Jang et al., “Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-ß,” The Journal of Immunology, vol. 178, no. 5, pp. 2883–2892, 2007. View at Google Scholar
  26. F. Baratelli, Y. Lin, L. Zhu et al., “Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells,” The Journal of Immunology, vol. 175, no. 3, pp. 1483–1490, 2005. View at Google Scholar
  27. M. Dohadwala, J. Luo, L. Zhu et al., “Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 20809–20812, 2001. View at Publisher · View at Google Scholar · View at PubMed
  28. M. Dohadwala, R. K. Batra, J. Luo et al., “Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion,” The Journal of Biological Chemistry, vol. 277, no. 52, pp. 50828–50833, 2002. View at Publisher · View at Google Scholar · View at PubMed
  29. H. Sheng, J. Shao, M. K. Washington, and R. N. DuBois, “Prostaglandin E2 increases growth and motility of colorectal carcinoma cells,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18075–18081, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. R. J. Durbin, “Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance,” Diabetes, Obesity & Metabolism, vol. 6, no. 4, pp. 280–285, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. A. Consoli and E. Devangelio, “Thiazolidinediones and inflammation,” Lupus, vol. 14, no. 9, pp. 794–797, 2005. View at Publisher · View at Google Scholar
  32. S. Schmidt, E. Moric, M. Schmidt, M. Sastre, D. L. Feinstein, and M. T. Heneka, “Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients,” Journal of Leukocyte Biology, vol. 75, no. 3, pp. 478–485, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. J. U. Scher and M. H. Pillinger, “15d-PGJ2: the anti-inflammatory prostaglandin?,” Clinical Immunology, vol. 114, no. 2, pp. 100–109, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. K. Inoue, Y. Kawahito, Y. Tsubouchi et al., “Expression of peroxisome proliferator-activated receptor (PPAR)-? in human lung cancer,” Anticancer Research, vol. 21, no. 4A, pp. 2471–2476, 2001. View at Google Scholar
  35. S. Theocharis, H. Kanelli, E. Politi et al., “Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade,” Lung Cancer, vol. 36, no. 3, pp. 249–255, 2002. View at Publisher · View at Google Scholar
  36. T. Yoshizumi, T. Ohta, I. Ninomiya et al., “Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects,” International Journal of Oncology, vol. 25, no. 3, pp. 631–639, 2004. View at Google Scholar
  37. V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor-? activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. Y. Bren-Mattison, A. M. Meyer, V. Van Putten et al., “Antitumorigenic effects of peroxisome proliferator-activated receptor-? in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-?B,” Molecular Pharmacology, vol. 73, no. 3, pp. 709–717, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Wick, G. Hurteau, C. Dessev et al., “Peroxisome proliferator-activated receptor-? is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth,” Molecular Pharmacology, vol. 62, no. 5, pp. 1207–1214, 2002. View at Publisher · View at Google Scholar
  40. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. M. Katori and M. Majima, “Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors,” Inflammation Research, vol. 49, no. 8, pp. 367–392, 2000. View at Publisher · View at Google Scholar
  42. H. R. Herschman, “Prostaglandin synthase 2,” Biochimica et Biophysica Acta, vol. 1299, no. 1, pp. 125–140, 1996. View at Publisher · View at Google Scholar
  43. K. Subbaramaiah, D. T. Lin, J. C. Hart, and A. J. Dannenberg, “Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300,” The Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440–12448, 2001. View at Publisher · View at Google Scholar · View at PubMed
  44. H. Inoue, T. Tanabe, and K. Umesono, “Feedback control of cyclooxygenase-2 expression through PPARγ,” The Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028–28032, 2000. View at Publisher · View at Google Scholar · View at PubMed
  45. N. Janabi, “Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Δ12,14-prostaglandin J2 in activated human astrocytes, but not in human brain macrophages,” The Journal of Immunology, vol. 168, no. 9, pp. 4747–4755, 2002. View at Google Scholar
  46. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Publisher · View at Google Scholar
  47. D. W. Gilroy, P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby, “Inducible cyclooxygenase may have anti-inflammatory properties,” Nature Medicine, vol. 5, no. 6, pp. 698–701, 1999. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Han, H. Inoue, L. C. Flowers, and N. Sidell, “Control of COX-2 gene expression through peroxisome proliferator-activated receptor γ in human cervical cancer cells,” Clinical Cancer Research, vol. 9, no. 12, pp. 4627–4635, 2003. View at Google Scholar
  49. M.-Y. Li, H. Deng, J.-M. Zhao, D. Dai, and X.-Y. Tan, “PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells,” World Journal of Gastroenterology, vol. 9, no. 6, pp. 1220–1226, 2003. View at Google Scholar
  50. G. He, Y. M. Sung, and S. M. Fischer, “Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 74, no. 3, pp. 193–197, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. E.-K. Yoon, W.-K. Lee, J.-H. Lee, S.-M. Yu, S.-G. Hwang, and S.-J. Kim, “ERK-1/-2 and p38 kinase oppositely regulate 15-deoxy-Δ12,14-prostaglandinJ2-induced PPAR-γ activation that mediates dedifferentiation but not cyclooxygenase-2 expression in articular chondrocytes,” Journal of Korean Medical Science, vol. 22, no. 6, pp. 1015–1021, 2007. View at Google Scholar
  52. H. Ikawa, H. Kameda, H. Kamitani et al., “Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells,” Experimental Cell Research, vol. 267, no. 1, pp. 73–80, 2001. View at Publisher · View at Google Scholar · View at PubMed
  53. E. A. Meade, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott, “Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells,” The Journal of Biological Chemistry, vol. 274, no. 12, pp. 8328–8334, 1999. View at Publisher · View at Google Scholar
  54. A. V. Pontsler, A. St. Hilaire, G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre, “Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor γ and oxidized alkyl phospholipids from oxidized low density lipoprotein,” The Journal of Biological Chemistry, vol. 277, no. 15, pp. 13029–13036, 2002. View at Publisher · View at Google Scholar · View at PubMed
  55. T. Kalajdzic, W. H. Faour, Q. W. He et al., “Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism,” Arthritis & Rheumatism, vol. 46, no. 2, pp. 494–506, 2002. View at Publisher · View at Google Scholar · View at PubMed
  56. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar · View at PubMed
  57. A. M. Lennon, M. Ramaugé, A. Dessouroux, and M. Pierre, “MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Δ12,14-prostaglandinJ2-prostaglandin J2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species,” The Journal of Biological Chemistry, vol. 277, no. 33, pp. 29681–29685, 2002. View at Publisher · View at Google Scholar · View at PubMed
  58. R. A. Nemenoff, “Peroxisome proliferator-activated receptor-γ in lung cancer: defining specific versus “off-target” effectors,” Journal of Thoracic Oncology, vol. 2, no. 11, pp. 989–992, 2007. View at Publisher · View at Google Scholar · View at PubMed
  59. S. T. Reddy, D. J. Wadleigh, and H. R. Herschman, “Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells,” The Journal of Biological Chemistry, vol. 275, no. 5, pp. 3107–3113, 2000. View at Publisher · View at Google Scholar
  60. J. A. Romashkova and S. S. Makarov, “NF-κB is a target of AKT in anti-apoptotic PDGF signalling,” Nature, vol. 401, no. 6748, pp. 86–90, 1999. View at Publisher · View at Google Scholar · View at PubMed
  61. L. V. Madrid, C.-Y. Wang, D. C. Guttridge, A. J. G. Schottelius, A. S. Baldwin, Jr., and M. W. Mayo, “Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB,” Molecular and Cellular Biology, vol. 20, no. 5, pp. 1626–1638, 2000. View at Publisher · View at Google Scholar
  62. K. M. Patel, K. L. Wright, P. Whittaker, P. Chakravarty, M. L. Watson, and S. G. Ward, “Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPARγ agonists: evidence for disparate functional effects which are independent of NF-κB and PPARγ,” Cellular Signalling, vol. 17, no. 9, pp. 1098–1110, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. D. A. Bradbury, L. Corbett, and A. J. Knox, “PI 3-kinase and MAP kinase regulate bradykinin induced prostaglandin E2 release in human pulmonary artery by modulating COX-2 activity,” FEBS Letters, vol. 560, no. 1–3, pp. 30–34, 2004. View at Publisher · View at Google Scholar · View at PubMed
  64. B.-C. Chen, Y.-S. Chang, J.-C. Kang et al., “Peptidoglycan induces nuclear factor-?B activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264.7 macrophages,” The Journal of Biological Chemistry, vol. 279, no. 20, pp. 20889–20897, 2004. View at Publisher · View at Google Scholar · View at PubMed
  65. S. A. Weaver, M. P. Russo, K. L. Wright et al., “Regulatory role of phosphatidylinositol 3-kinase on TNF-a-induced cyclooxygenase 2 expression in colonic epithelial cells,” Gastroenterology, vol. 120, no. 5, pp. 1117–1127, 2001. View at Publisher · View at Google Scholar · View at PubMed
  66. H. Cho and H.-H. Tai, “Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 67, no. 6, pp. 461–465, 2002. View at Publisher · View at Google Scholar
  67. R. L. Keith, Y. E. Miller, T. M. Hudish et al., “Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice,” Cancer Research, vol. 64, no. 16, pp. 5897–5904, 2004. View at Publisher · View at Google Scholar · View at PubMed
  68. A. Finckh and M. D. Aronson, “Cardiovascular risk of cyclooxygenase-2 inhibitors: where we stand now,” Annals of Internal Medicine, vol. 142, no. 3, pp. 212–214, 2005. View at Google Scholar
  69. J. T. Mao, I.-H. Tsu, S. M. Dubinett et al., “Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide,” Clinical Cancer Research, vol. 10, no. 20, pp. 6872–6878, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. R. N. DuBois, S. B. Abramson, L. Crofford et al., “Cyclooxygenase in biology and disease,” The FASEB Journal, vol. 12, no. 12, pp. 1063–1073, 1998. View at Google Scholar
  71. S. Han and J. Roman, “Suppression of prostaglandin E2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth,” Biochemical and Biophysical Research Communications, vol. 314, no. 4, pp. 1093–1099, 2004. View at Publisher · View at Google Scholar
  72. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476–1481, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. C. J. Rosen, “The rosiglitazone story—lessons from an FDA advisory committee meeting,” The New England Journal of Medicine, vol. 357, no. 9, pp. 844–846, 2007. View at Publisher · View at Google Scholar · View at PubMed
  74. “Thiazolidinediones and cardiovascular disease,” The Medical Letter on Drugs and Therapeutics, vol. 49, no. 1265, pp. 57–58, 2007.
  75. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at PubMed
  76. R. A. Nemenoff, M. Weiser-Evans, and R. A. Winn, “Activation and molecular targets of peroxisome proliferator-activated receptor-γ ligands in lung cancer,” PPAR Research, vol. 2008, Article ID 156875, 8 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  77. K. A. Peebles, J. M. Lee, J. T. Mao et al., “Inflammation and lung carcinogenesis: applying findings in prevention and treatment,” Expert Review of Anticancer Therapy, vol. 7, no. 10, pp. 1405–1421, 2007. View at Publisher · View at Google Scholar · View at PubMed
  78. H.-S. Kim, H.-R. Youm, J.-S. Lee, K.-W. Min, J.-H. Chung, and C.-S. Park, “Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer,” Lung Cancer, vol. 42, no. 2, pp. 163–170, 2003. View at Publisher · View at Google Scholar
  79. F. R. Khuri, H. Wu, J. J. Lee et al., “Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer,” Clinical Cancer Research, vol. 7, no. 4, pp. 861–867, 2001. View at Google Scholar
  80. H. Tsubochi, N. Sato, M. Hiyama et al., “Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer,” The Annals of Thoracic Surgery, vol. 82, no. 4, pp. 1198–1204, 2006. View at Publisher · View at Google Scholar · View at PubMed